SK286821B6 - Bunkový systém na in vivo expresiu interferónu beta a farmaceutický prípravok obsahujúci tento systém - Google Patents

Bunkový systém na in vivo expresiu interferónu beta a farmaceutický prípravok obsahujúci tento systém Download PDF

Info

Publication number
SK286821B6
SK286821B6 SK248-2000A SK2482000A SK286821B6 SK 286821 B6 SK286821 B6 SK 286821B6 SK 2482000 A SK2482000 A SK 2482000A SK 286821 B6 SK286821 B6 SK 286821B6
Authority
SK
Slovakia
Prior art keywords
interferon
cells
gene
vector
tumor
Prior art date
Application number
SK248-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK2482000A3 (en
Inventor
James G. Barsoum
Xiao-Qiang Qin
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of SK2482000A3 publication Critical patent/SK2482000A3/sk
Publication of SK286821B6 publication Critical patent/SK286821B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK248-2000A 1997-08-29 1998-08-25 Bunkový systém na in vivo expresiu interferónu beta a farmaceutický prípravok obsahujúci tento systém SK286821B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29
PCT/US1998/017606 WO1999010516A2 (en) 1997-08-29 1998-08-25 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Publications (2)

Publication Number Publication Date
SK2482000A3 SK2482000A3 (en) 2000-08-14
SK286821B6 true SK286821B6 (sk) 2009-06-05

Family

ID=22009467

Family Applications (1)

Application Number Title Priority Date Filing Date
SK248-2000A SK286821B6 (sk) 1997-08-29 1998-08-25 Bunkový systém na in vivo expresiu interferónu beta a farmaceutický prípravok obsahujúci tento systém

Country Status (25)

Country Link
EP (1) EP1007717B8 (is)
JP (3) JP4124565B2 (is)
KR (1) KR100699285B1 (is)
CN (1) CN100342019C (is)
AT (1) ATE316145T1 (is)
AU (1) AU740428B2 (is)
BR (1) BR9812138A (is)
CA (1) CA2300480C (is)
CY (1) CY1105029T1 (is)
CZ (2) CZ297314B6 (is)
DE (1) DE69833264T2 (is)
DK (1) DK1007717T3 (is)
EA (1) EA003256B1 (is)
EE (1) EE04873B1 (is)
ES (1) ES2257817T3 (is)
HK (1) HK1029599A1 (is)
HU (1) HU224422B1 (is)
IL (2) IL134593A0 (is)
IS (1) IS2318B (is)
NO (1) NO20000990L (is)
NZ (1) NZ503401A (is)
PT (1) PT1007717E (is)
SK (1) SK286821B6 (is)
TR (1) TR200000532T2 (is)
WO (1) WO1999010516A2 (is)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1363676B1 (en) 2001-01-22 2007-03-28 Biogen Idec MA Inc. Method of enhancing delivery of a therapeutic nucleic acid
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
KR20220025757A (ko) * 2019-06-01 2022-03-03 시벡 바이오테크놀로지스, 엘엘씨 진핵 세포에 유전자 편집 시스템을 전달하기 위한 박테리아 플랫폼

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
EP0707071B1 (en) * 1994-08-16 2003-07-30 Crucell Holland B.V. Recombinant vectors derived from adenovirus for use in gene therapy
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
JP2005225888A (ja) 2005-08-25
TR200000532T2 (tr) 2000-11-21
SK2482000A3 (en) 2000-08-14
AU740428B2 (en) 2001-11-01
BR9812138A (pt) 2000-07-18
DK1007717T3 (da) 2006-05-29
IL134593A (en) 2007-06-17
EA003256B1 (ru) 2003-02-27
EE04873B1 (et) 2007-08-15
IS2318B (is) 2007-11-15
WO1999010516A3 (en) 1999-05-06
EP1007717A2 (en) 2000-06-14
DE69833264D1 (de) 2006-04-06
HUP0002913A2 (hu) 2000-12-28
HK1029599A1 (en) 2001-04-06
HUP0002913A3 (en) 2003-08-28
EE200000102A (et) 2000-12-15
NZ503401A (en) 2003-01-31
CN100342019C (zh) 2007-10-10
CZ299095B6 (cs) 2008-04-23
CA2300480A1 (en) 1999-03-04
AU9205198A (en) 1999-03-16
JP2004155786A (ja) 2004-06-03
EP1007717B1 (en) 2006-01-18
IL134593A0 (en) 2001-04-30
PT1007717E (pt) 2006-06-30
HU224422B1 (hu) 2005-08-29
EP1007717B8 (en) 2006-05-03
JP2001514010A (ja) 2001-09-11
NO20000990D0 (no) 2000-02-28
KR20010023511A (ko) 2001-03-26
CA2300480C (en) 2010-01-05
IS5374A (is) 2000-02-11
WO1999010516A2 (en) 1999-03-04
CZ2000733A3 (cs) 2000-06-14
JP4219335B2 (ja) 2009-02-04
NO20000990L (no) 2000-05-02
ATE316145T1 (de) 2006-02-15
CN1271391A (zh) 2000-10-25
EA200000270A1 (ru) 2000-10-30
JP4124565B2 (ja) 2008-07-23
CZ297314B6 (cs) 2006-11-15
DE69833264T2 (de) 2006-09-28
ES2257817T3 (es) 2006-08-01
CY1105029T1 (el) 2010-03-03
JP3953458B2 (ja) 2007-08-08
KR100699285B1 (ko) 2007-03-26

Similar Documents

Publication Publication Date Title
JP4219335B2 (ja) インターフェロンβのような分泌タンパク質をコードする遺伝子を使用する治療のための方法および組成物
US20040038404A1 (en) Recombinant adenoviral vector and methods of use
NZ275956A (en) A recombinant adenovirus expression vector useful against tumours
PL186018B1 (pl) Sposoby i kompozycje do diagnozowania i leczenia nowotworu
US20080166373A1 (en) METHODS AND COMPOSITIONS FOR DELIVERY AND EXPRESSION OF INTERFERON-alpha NUCLEIC ACIDS
US7256181B2 (en) Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US20040266006A1 (en) Adenoviral vectors having a protein IX deletion
SK50699A3 (en) Methods and compositions for delivery and expression of interferon-'alpha' nucleic acids
EP1679375A1 (en) Methods and compositions for cancer therapies using genes encoding interferon-beta
US20030091534A1 (en) Adenoviral vectors having a protein IX deletion
MXPA00002101A (es) Metodos y composiciones para terapias que utilizan genes que codifican proteinas secretadas como beta-interferon
EP0879294A1 (en) Transduced human hematopoietic stem cells
US20020137212A1 (en) Adenoviral vectors having a protein IX deletion
AU3521101A (en) Methods and compositions for delivery and expression of interferon-alpha nucleic acids

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20100825